What you are comparing
This comparison is not stem cells versus no science. It is FDA-approved or trial-supervised uses versus cash-pay clinic offerings marketed for aging, pain, neurologic disease, or general regeneration. Those are different products, different evidence, and different legal status. The word stem cell does not make them the same.
FDA-approved stem cell products in the United States are limited. The agency’s consumer materials emphasize blood-forming, or hematopoietic, stem cells from sources such as umbilical cord blood for specific hematologic uses. Those products go through review. They are not a general anti-aging injection, and they are not sold as a wellness add-on.
Many clinics market unapproved products recovered from fat, bone marrow, cord tissue, amniotic fluid, or another person’s cells, and some now add exosomes. FDA states that these products generally require licensure or approval to be marketed to treat disease, and that there are currently no FDA-approved exosome products. Same-day orthopedic or IV packages are usually in this unapproved group.
ISSCR, the International Society for Stem Cell Research, tells patients that most advertised treatments have not been shown to be safe or effective in rigorous trials. Some products have not even been shown to contain stem cells. The comparison that matters is regulatory status and trial evidence, not a before-and-after photo.
How they differ
Oversight is the first difference. An approved product has manufacturing standards and labeled indications. A registered trial has a protocol, eligibility rules, and safety reporting. An unapproved clinic product may be processed in a way FDA still regulates as a drug or biologic, even if the clinic calls it your own cells or minimal manipulation.
Claims are the second difference. Approved labels are narrow. Unapproved marketing is often broad: joints, brain, lungs, autism, fatigue, and aging in one brochure. FDA’s patient pages list many conditions for which regenerative products are not approved, including osteoarthritis, neurologic disease, chronic pain, and macular degeneration. Breadth of claims is a warning, not a feature.
Cost and consent also differ. Transplant and oncology uses are medical procedures with hospital oversight and, often, insurance review. Unapproved clinic visits are commonly cash-pay and may cost thousands to tens of thousands of dollars. Payment is not consent to an experiment, and a waiver does not make an illegal product legal.
Follow-up differs too. Trial and hospital programs record adverse events. A wellness clinic may have no plan for infection, vision change, or a new mass. If you cannot name who admits you at 2 a.m., you do not have the same safety net as approved care, regardless of how clinical the room looks.
Who each option is for
Approved hematopoietic stem cell transplantation is for specific blood cancers and some blood or immune disorders, directed by specialists in that field. It is intensive, has real toxicity, and is not a longevity elective. If that is your diagnosis, the conversation belongs with hematology or transplant—not a cash-pay regeneration spa.
A registered clinical trial may fit if you have a condition under study, you meet eligibility rules, and you understand you may receive a placebo or an investigational product that might not help. You should still keep your usual clinicians involved. Paying a large fee to “join research” at a marketing clinic is not the same as a trial.
Unapproved anti-aging or orthopedic stem cell packages are not a fit if you want a proven therapy, if you cannot afford a loss, or if you have an infection risk, cancer history, or a condition with a standard treatment you have not tried. They are also a poor fit if the clinic treats many unrelated diagnoses with one product.
People with joint pain, fatigue, or neurologic symptoms still need a diagnosis. Physical therapy, indicated imaging, disease-modifying drugs, or pain-management standards may be the evidence-based path. Stem cell language should not skip that workup. If you are considering a trial, bring the protocol to the clinician who already knows you.
Risks of choosing the wrong one
FDA has received reports of infection, blindness, tumor formation, and death after unapproved cell or tissue products. Contamination during processing and injection into the wrong site are part of that record. Autologous source does not erase those events. The harm can be permanent.
Financial harm is common even when the medical outcome is only “no change.” You may pay for travel, repeats, and add-on exosomes or IV vitamins. That money is then unavailable for physical therapy, indicated surgery consults, or medications that do have evidence. Opportunity cost is a clinical risk, not only a budget issue.
Delay is the third harm. Months spent waiting for a regeneration package can postpone cancer evaluation, infection treatment, or rehabilitation. FDA notes that unapproved marketing can keep people from legitimate options. A clinic that tells you standard care has failed because it is not regenerative is asking you to trade a known path for an unreviewed one.
False reassurance is a risk of its own. Calling a product natural, organic, or from your own body can hide that FDA still regulates it as an unapproved drug or biologic. Exosome add-ons do not fix that problem. There are no FDA-approved exosome products, and FDA has warned about serious events linked to those offerings.
How to decide
Ask whether the exact product is FDA-approved for your condition, or whether you would be in a trial registered and overseen as research. If the answer is that approval is not needed because the cells are yours, treat that as a claim to verify—not as a conclusion. FDA’s consumer pages are written for that exact conversation.
Use ISSCR’s patient guide as a question list: What cells are used? How were they processed? What published trials support this use? Who reviews adverse events? What happens if you are harmed? A clinic that cannot answer in plain language, or that treats many unrelated diseases with one vial, is the wrong setting.
Keep your usual licensed clinicians in the loop. Bring the consent form and product name to your primary care clinician or the relevant specialist before you pay. If they have not heard of the product as an approved therapy, that is useful information. Do not stop indicated treatment to make room for an unapproved injection.
If you already received an unapproved product and you have fever, vision change, severe pain, a new lump, or neurologic symptoms, seek urgent or emergency care and say what was injected. FDA’s MedWatch program exists so those events can be reported. Reporting does not undo harm, but it is part of protecting the next patient.
Frequently Asked Questions
References
FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesFDA: Important Patient and Consumer Information About Regenerative Medicine Therapies
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapiesFDA: Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products
https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-productsISSCR: Guide to Stem Cell Treatments
https://www.aboutstemcells.org/patient-guide
Your Privacy Choices